Zydus Cadila

Zydus Cadila


More Stories on Zydus Cadila

Zydus Cadila MD shares plans for vaccine trials in children below 12 years

Aug 23, 2021

Zydus Cadila announced on Saturday that they will start producing one crore doses of Covid-19 vaccine by October. Zydus Cadila MD Dr Sharvil Patel also broke the news to India Today that the company will now apply to start the trial of its Covid-19 vaccine in children of age group 3-12.

The vaccine roll-out is likely to start by mid or end of September

Post DCGI nod, Zydus Cadila to start COVID vaccine trial on children aged 3-12 yrs

Aug 22, 2021

ZyCoV-D is a three-dose, needle-free vaccine, and is also the world's first plasmid DNA-based medicine. Developed in partnership with the Department of Biotechnology, it is India's second locally developed vaccine to receive EUA after Bharat Biotech's Covaxin

The company is in discussions with 2-3 other Indian manufacturers for technology transfer to scale up production

Zydus to commercialise Zycov-D next month, scale up production to 1 cr by Oct

Aug 21, 2021

Dr Sharvil Patel, managing director, Zydus Cadila said the company has started production in small batches and is stockpiling 2-3 million doses of the vaccine from its new facility set up at Ahmedabad

 Zydus Cadila plans to manufacture 10-12 crore doses of ZyCoV-D annually

Zydus Cadila's COVID-19 vaccine nod a global first in plasmid DNA jabs

Aug 21, 2021

Zydus Cadila says this is for the first time that a technologically advanced vaccine has been successfully developed on the Plasmid DNA platform for human use

 With the emergency use authorisation (EUA), ZyCoV-D has also become the first vaccine to be administered to those in the age group of 12-18 years in the country

'A momentous feat': PM Modi after Zydus Cadila's COVID-19 vaccine gets approval

Aug 21, 2021

Prime Minister Narendra Modi said the approval to the world's first DNA-based vaccine against the coronavirus is a testimony to the innovative zeal of India's scientists

The generic drugmaker, listed as Cadila Healthcare Ltd, applied for the authorisation of the vaccine ZyCoV-D on July 1

COVID-19 vaccine: SEC recommends emergency approval for Zydus Cadila's ZyCoV-D

Aug 20, 2021

The committee added that Zydus needs to submit additional data for the 2-dose regimen of its vaccine

On its COVID-19 portfolio, Zydus Cadila said it has undertaken research in monoclonal antibodies cocktail to neutralise COVID infection.

Zydus Cadila Q1 net profit rises 29% to Rs 587 cr, revenue up 15%

Aug 11, 2021

The pharma company's revenue from operations rose 15 per cent YoY to Rs 4,025 crore, while EBITDA jumped 18 per cent to Rs 933 crore.

The study, including the clinical trials, will be held by the Christian Medical College, Vellore.

DCGI nod to study on mixing of Covishield, Covaxin: Sources

Aug 10, 2021

On July 29, Central Drugs Standard Control Organisation's Subject Expert Committee had recommended a study on mixing of both Covid-19 vaccines

ZyCoV-D is a DNA plasmid vaccine, which uses a portion of the genetic code -- DNA or RNA -- in the virus to stimulate an immune response.

Zydus Cadila's COVID-19 vaccine likely to get approval this week

Aug 09, 2021

Zydus Cadila had on July 1 announced that it had applied for emergency use authorisation (EUA) of its ZyCoV-D three-dose COVID-19 vaccine.

This study will be conducted to assess whether a beneficiary can be administered one shot each of Covishield and Covaxin to complete the vaccination course

COVID-19 vaccine: Govt panel approves trial to mix Covishield, Covaxin doses

Jul 30, 2021

This study will be conducted to assess whether a beneficiary can be administered one shot each of Covishield and Covaxin to complete the vaccination course

The trial is being conducted by categorising children as per their age wherein 175 children of each age group have been included

Results of Covaxin trials on children expected by Sept: AIIMS chief

Jul 24, 2021

"The vaccines for children should come out now because trials in India are already there in the vaccines which are available in India, the Bharat Biotech trial is in the final phase by September we will have the data," Dr Guleria told ANI